Skip to main content

Table 3 Baseline serum cytokines in Cohort 2 (sorafenib-treated patients)

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Cytokines (pg/mL, mean ± SE) Survival time ≥ 2 years(n = 7) Survival time < 2 years(n = 32) P-valuea
EGF 213.7 ± 99.5 58.3 ± 10.6 0.004
FGF 89.6 ± 46.8 103.4 ± 19.4 0.770
HGF 483.4 ± 111.9 313.0 ± 45.8 0.133
IFN-γ 23.2 ± 4.2 16.0 ± 1.8 0.103
IL-10 32.1 ± 10.6 16.2 ± 1.7 0.012
IL-12 (p70) 23.0 ± 4.3 14.6 ± 1.6 0.039
IL-2 50.8 ± 12.0 34.1 ± 3.7 0.093
IL-4 18.9 ± 3.5 13.2 ± 1.5 0.132
IL-5 20.3 ± 4.8 14.4 ± 2.1 0.246
IL-6 25.2 ± 7.5 18.2 ± 2.4 0.270
IL-8/CXCL8 80.1 ± 36.3 37.1 ± 5.5 0.039
CXCL10 1078.6 ± 339.9 631.9 ± 116.2 0.136
CXCL9 345.3 ± 65.8 241.8 ± 32.1 0.178
PDGF-BB 620.6 ± 250.4 171.0 ± 31.6 0.001
SCF 78.9 ± 12.8 48.0 ± 5.3 0.021
SDF-1 876.0 ± 148.1 549.1 ± 54.1 0.020
TGF-β 32.4 ± 6.4 23.2 ± 2.5 0.143
TGF-α 31.6 ± 11.5 16.2 ± 1.8 0.020
TNF-α 22.9 ± 8.0 13.0 ± 1.4 0.042
VEGF-A 94.6 ± 10.2 86.7 ± 17.9 0.841
  1. SE standard error
  2. aUnpaired t-tests